23 research outputs found
Estudio de la productividad laboral en Castilla y LeĂłn
El propĂłsito de este Trabajo Fin de Grado es estudiar el comportamiento de la productividad laboral en Castilla y LeĂłn por trimestre entre los años 2000 y 2013, definiendo como productividad laboral el cociente de la producciĂłn y el nĂșmero de trabajadores (ocupados).
Antes de analizar el comportamiento de la productividad laboral se realizarĂĄ un estudio sobre la evoluciĂłn de las variables que influyen sobre la misma, que nos ayudarĂĄ posteriormente a comprender la evoluciĂłn de la productividad.
Una vez realizada la evoluciĂłn de la productividad, nos detendremos en la bĂșsqueda de un modelo que nos ayude a analizar y predecir el comportamiento de la productividad tanto en Castilla y LeĂłn como a nivel nacional.
Todos los estudios se realizarĂĄn sobre el total de la productividad y por sector de actividad. Los sectores de actividad que se han incluido en el estudio son: sector primario (que reĂșne a la agricultura, ganaderĂa y pesca), sector industrial, sector construcciĂłn y sector servicios.Grado en EstadĂstic
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naĂŻve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naĂŻve participants after two doses than in Rec after a single dose (pâ<â0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (pâ<â0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.This work is funded by Instituto de Salud Carlos III, a Spanish public body assigned to the Ministry of Science and Innovation that manages and promotes public clinical research related to Public Health, by Grants PI19CIII/00004 (JosĂ© AlcamĂ and Francisco DĂezâFuertes) and PI21CIII/00025 (Javier GarcĂaâPĂ©rez and Mayte PĂ©rezâOlmeda), COVIDâ19 Fund (Grants COV20/00679 (Javier GarcĂaâPĂ©rez, Mayte PĂ©rezâOlmeda, JosĂ© AlcamĂ, and Francisco DĂezâFuertes) and COV20/00072 (Javier GarcĂaâPĂ©rez, Mayte PĂ©rezâOlmeda, Almudena RamĂrezâGarcĂa, MarĂa Castillo de la Osa, Rocio Layunta Acero, Laura VicenteâIzquierdo, Cristina AvendañoâSolĂĄ, and JosĂ© AlcamĂ), and CIBERINFEC, coâfinanced by the European Regional Development Fund (FEDER) âA way to make Europe.âS
Effect of an Intensive Weight-Loss Lifestyle Intervention on Kidney Function: A Randomized Controlled Trial
Introduction: Large randomized trials testing the effect of a multifactorial weight-loss lifestyle intervention including Mediterranean diet (MedDiet) on renal function are lacking. Here, we evaluated the 1-year efficacy of an intensive weight-loss intervention with an energy-reduced MedDiet (erMedDiet) plus increased physical activity (PA) on renal function. Methods: Randomized controlled "PREvenciĂłn con DIeta MEDiterrĂĄnea-Plus"(PREDIMED-Plus) trial is conducted in 23 Spanish centers comprising 208 primary care clinics. Overweight/obese (n = 6,719) adults aged 55-75 years with metabolic syndrome were randomly assigned (1:1) to an intensive weight-loss lifestyle intervention with an erMedDiet, PA promotion, and behavioral support (intervention) or usual-care advice to adhere to an energy-unrestricted MedDiet (control) between September 2013 and December 2016. The primary outcome was 1-year change in estimated glomerular filtration rate (EGFR). Secondary outcomes were changes in urine albumin-to-creatinine ratio (UACR), incidence of moderately/severely impaired EGFR (<60 mL/min/1.73 m2) and micro-to macroalbuminuria (UACR â„30 mg/g), and reversion of moderately (45 to <60 mL/min/1.73 m2) to mildly impaired GFR (60 to <90 mL/min/1.73 m2) or micro-to macroalbuminuria. Results: After 1 year, EGFR declined by 0.66 and 1.25 mL/min/1.73 m2 in the intervention and control groups, respectively (mean difference, 0.58 mL/min/1.73 m2; 95% CI: 0.15-1.02). There were no between-group differences in mean UACR or micro-to macroalbuminuria changes. Moderately/severely impaired EGFR incidence and reversion of moderately to mildly impaired GFR were 40% lower (HR 0.60; 0.44-0.82) and 92% higher (HR 1.92; 1.35-2.73), respectively, in the intervention group. Conclusions: The PREDIMED-Plus lifestyle intervention approach may preserve renal function and delay CKD progression in overweight/obese adults.This work was supported by the official Spanish Institutions for funding scientific biomedical research, CIBER FisiopatologĂa de la Obesidad y NutriciĂłn (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), through the Fondo de InvestigaciĂłn para la Salud (FIS), which is cofunded by the European Regional Development Fund (5 coordinated FIS projects leaded by J.S.-S and J.V., including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926; PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, and PI19/01332); the Especial Action Project entitled ImplementaciĂłn y evaluaciĂłn de una intervenciĂłn intensiva sobre la actividad fĂsica Cohorte PREDIMED-Plus grant to J.S.-S.; the European Research Council (Advanced Research Grant 2014â2019; agreement #340918) granted to M.Ă.M.-G.; the Recercaixa (No. 2013ACUP00194) grant to J.S.-S.; grants from the ConsejerĂa de Salud de la Junta de AndalucĂa (PI0458/2013, PS0358/2016, and PI0137/2018); the PROMETEO/2017/017 grant from the Generalitat Valenciana; the SEMERGEN grant; funds from the European Regional Development Fund (CB06/03); International Nut & Dried Fruit Council â FESNAD (Long-term effects of an energyrestricted Mediterranean diet on mortality and cardiovascular disease 2014â2015, No. 201302) (PI: M.Ă.M.-G.); the AstraZeneca Young Investigators Award in Category of Obesity and T2D 2017 (PI: D.R.); grant of support to research groups No. 35/2011 (Balearic Islands Gov.; FEDER funds) (J.A.T. and C.B.); the JR17/00022 (ISCIII) grant to O.C.; the Boosting young talent call grant program for the development of IISPV research projects 2019â2021 (Ref.: 2019/IISPV/03 grant to A.D.-L.); the Societat Catalana dâEndocrinologia i NutriciĂł (SCEN) Clinical-Research Grant 2019 (IPs: J.S.-S. and A.D.-L.). Collaborative Nutrition and/or Obesity Project for Young Researchers 2019 supported by CIBEROBN entitled Lifestyle Interventions and Chronic Kidney Disease: Inflammation, Oxidative Stress and Metabolomic Profile (LIKIDI study) grant to A.D.-L
Aula itinerante de Patrimonio Cultural II
Memoria final del PIMCD UCM 2020/2021 nĂșmero 31
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.
Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).
Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001).
Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio
A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)
Meeting abstrac
Body composition analysis and adipocytokine concentrations in haemodialysis patients: Abdominal fat gain as an added cardiovascular risk factor. Abdominal fat gain and cardiovascular risk
Introduction: Abdominal fat and its increment over time in particular has become a cardiovascular risk factor in uraemic patients.
Objectives: To analyse changes in abdominal fat in haemodialysis patients over one year and study their possible correlation with the variation in adipocytokine serum levels. As a secondary objective, we tried to validate the data obtained by bioelectrical impedance analysis (BIA) with data obtained by dual X-ray absorptiometry (DXA).
Material and methods: A prospective one-year study was performed in 18 patients on haemodialysis (HD). In each patient, body composition by BIA and DXA was estimated at baseline and after one year. Several adipocytokine and biochemical parameters were determined.
Results: A significant increase in phase angle [4.8° (4.1â5.6) vs. 5.2° (4.4â5.8), p < 0.05], BIA intracellular water [48.3% (43.1â52.3) vs. 50.3% (45.7â53.4), p < 0.05] and the ratio between the percentage of android/gynecoid (A/G) distribution of fat measured by DXA [1.00 (0.80â1.26) vs. 1.02 (0.91â1.30), p < 0.05] was observed. A statistically significant relationship between leptin and adiponectin concentrations and the percentage of fat mass measured by BIA, as well as the abdominal fat percentage estimated by DXA, was found (p < 0.01).
Conclusion: HD patients exhibit a gain in fat mass over time, especially in the abdomen, evidenced by an increased A/G ratio. These findings might explain the increased cardiovascular risk in these patients